Introduction -Page 6 line 54 -I think reference 6 is the wrong one here? -Page 7: o H1 is not clearly stated -you need to state whether you are focussing on the HAI or the mini AHA. o secondary outcomes differ between the aims and secondary hypotheses section (PEDICAT).
o Background section from bottom of page 8: too long, needs condensing. The last paragraph of the introduction is not very clear and not well referenced. o The introduction does not capture the current lack of any gold standard in treatment of this group of infants. Methods Inclusion/exclusion criteria -please clarify the differences from those stated at trial registration, including the issue about patients with a VP shunt. P16-18: theoretical framework of baby CIMT and baby BIM: this would be better in the Introduction and could be condensed, as could the section on implementation and use of assessment information for treatment planning. P 20: Home program is optimal for best practice: I agree in general with this philosophy but you have not provided supporting evidence. P24: each therapist will have a PI? (not CI?) at each site Delivery and fidelity: it must be possible to condense this section for clarity Classification of the brain lesion: likewise: details on Fiori scale are published elsewhere. Page 30: assessments for eligibility for study entry -this should be combined with the eligibility section. The section on the Kidokoro scale comes a little "left wing" after the Fiori scale and other descriptions of how eligibility by imaging will be tackled. Primary outcome -Test retest reliability at school age for AHA is presumably not the same as test retest reliability for the mini AHA at 12 months. -Secondary outcome: these also differ in parts from those in the registration details, which is worth explaining for clarity -Statistical analysis o Page 35 line 32-why does it say that the primary comparison at 12 months will be based on the mini AHA and BSIDIII scores? Everywhere else, the primary outcome is stated as mini AHA. -Ethical approvals: are mentioned twice (once at the start of the methods and once at the end) and in fact again on page 41.
-Figures 1 and 2 are probably unnecessary
Minor points There are some typos and other errors to sort -e.g. confusion over < and > signs; spelling of "asymmetries"; practice vs practise; other issues to proofread out.
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GENERAL COMMENTS
This protocol describes the conduct of an important research project that could have a profound impact on rehabilitation of children with unilateral cerebral palsy, and could achieve potentially large benefits for their independence and quality of life. The protocol appears robust and is thorough. I have raised a small number of points to consider. I note that you are stratifying children for the randomisation process. This is stated in the flow diagram but not in the Methods section. It is essential that all of the stratifying factors are listed in this protocol.
Have you considered children"s MACS level as a stratifying factor? Please also list a priori all covariates for the regression analyses. It is essential to carefully consider all possible confounding and interacting factors and list them prior to the study and prior to the analyses. I suggest that dose received is not a confounding factor (it has an influence on the outcome but not on the exposure, and is therefore a mediator). Thank you for including your power calculations but they do not take into account the covariates which you will include in the regression analyses, the number of which will have an inverse influence on the RCT"s power. It would be devastating to conduct this study only to find it is drastically underpowered and the results worthless. Is the GMFCS necessary as well as MACS? I am not sure that it is even appropriate at the age at which you are recruiting your children but will it add anything useful? I also have doubts about the Prechtl's assessment of general movements as a study assessment for inclusion criteria. If used on all infants born in the recruitment period it would give an entirely unsatisfactory indication of children likely to develop neurodevelopmental outcomes (approximately 1 in 26 of the children it suggests will have neurodevelopmental problems will go on to develop them, based on 95% sensitivity and specificity 
In general, I am not really in favor of publishing 'study plans', but this appears to be a current trend. The paper is well written and presented and the study protocol and plans are excellent.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Anna Basu Institution and Country: Newcastle University, Newcastle upon Tyne, UK Please state any competing interests or state "None declared": I have developed and am undertaking a pilot feasibility study of a parent-delivered early intervention in infants at high risk of developing unilateral CP following brain lesions such as perinatal stroke. This is funded through an NIHR Career Development Fellowship.
We note the reviewers publication on Trial Protocols: In Basu et al. Trials (2017) 18:5 DOI 10.1186/s13063-016-1757-7. Publishing protocols for trials of complex interventions before trial completion -potential pitfalls, solutions and the need for public debate Anna Purna Basu1,2*, Janice Elizabeth Pearse3 and Tim Rapley4
1. This manuscript describes the protocol for a randomised trial of rehabilitation very early in congenital hemiplegia. The trial is already up and running and was registered prospectively (Please note the weblink provided in the manuscript is in fact to a different trial, namely MITI) -from this, the last patient was due to be enrolled in early April 2017. 2. Whilst the authors are clearly undertaking a substantial piece of work, the manuscript is very lengthy (9449) words, repetitive and in places unfocussed. Much of the basic science and principles referred to are covered in detail in reviews elsewhere (including some written by myself). I would strongly recommend rationalising and paring down the manuscript, removing unnecessary figures and improving the flow of logic -this would hugely strengthen the writing and aid the reader. Also any deviation from the details in the registered trial need to be clarified and greater consistency achieved between intended goals stated in various sections of the manuscript.
Response: The authors take this as a comment, as we believe the background neuroscience and principles provide a strong rationale for performing this novel trial. This background material was prepared when the study was submitted in February 2015 and subsequently achieved funding from our National Health and Medical Research Council for the trial and is therefore considered to be important rationale for undertaking this RCT in infants at risk of hemiplegia. The level of detail for this protocol is also required in order to meet the TiDIER guidelines for quality of reporting. Response: We believe that H1 is correct, as it is a composite of both unimanual capacity best measured on the HAI, and bimanual co-ordination measured on the Mini-AHA at 12 months C.A.
• secondary outcomes differ between the aims and secondary hypotheses section (PEDICAT). Response: The secondary aim has been amended to read:
Our secondary aim is to determine if there is a differential impact of Baby mCIMT and Baby BIM on early cognitive and fine motor development (Bayley III) and better participation in play, self-care activities and social functioning (Pediatric Evaluation of Disability Inventory Computer Adapted Test, PEDI-CAT) in association with early brain reorganisation (dMRI at 24 months c.a.).
• Background section from bottom of page 8: too long, needs condensing. The last paragraph of the introduction is not very clear and not well referenced. Response: For a protocol paper that outlines the rational, theoretical underpinnings of the proposed trial from both relevant basic science studies and randomised trials of upper limb intervention for children with UCP (from bottom page 8-11, in all a total of 3 pages) is not we believe lengthy and is representative of the scientific rationale. In our background we have focussed on clinical trials and published evidence from clinical trials in UCP. We understand this reviewer may wish us to refer to her review article on this topic, so we have added this to page 11, With our response to our next comment.
• The introduction does not capture the current lack of any gold standard in treatment of this group of infants.
Response: We agree and have added to the end of our introduction on page 11: As evidence supports alternative approaches, mCIMT from animal studies and BIM from advanced MRI, in addition to the marked lack of evidence for an effective treatment for infants at risk of The exclusion criteria are: 1. Epilepsy uncontrolled by medication at study entry 2. Infants with severe or profound functional visual impairment (assessed on a visual tracking task at baseline between 3 and 6 months of age) 3. Ventriculo-peritoneal shunts.
P16-18: theoretical framework of baby CIMT and baby BIM: this would be better in the Introduction and could be condensed, as could the section on implementation and use of assessment information for treatment planning.
Response: This a preference of this reviewer, we respectfully disagree and feel that all information for the theoretical frameworks of each intervention, and implementation of the intervention is much better placed in the sections about the intervention (to avoid duplication from Background). Page 30: assessments for eligibility for study entry -this should be combined with the eligibility section. The section on the Kidokoro scale comes a little "left wing" after the Fiori scale and other descriptions of how eligibility by imaging will be tackled.
Response: This section has been reframed as Baseline Assessments and have moved these to page 28 prior to the classification of the sample (which occurs at 12 and 24 months) to place the Kiddokorro neonatal MRI scale in context before the Fiori scale of brain lesion severity which is performed on the 24 month scans. We do not believe it fits with the inclusion criteria.
Primary outcome -Test retest reliability at school age for AHA is presumably not the same as test retest reliability for the mini AHA at 12 months. Response: This is correct and as test-retest reliability of the mini-AHA at 12 months has not been published this is why it is included here.
-Secondary outcome: these also differ in parts from those in the registration details, which is worth explaining for clarity. In the trial registration: there have been some modifications highlighted here which were updated. Statistical analysis o Page 35 line 32-why does it say that the primary comparison at 12 months will be based on the mini AHA and BSIDIII scores? Everywhere else, the primary outcome is stated as mini AHA.
Response: This was an error and has been changed to:
The primary outcome, mini-AHA scores at 12 months c.a., will be compared between treatment groups using generalized linear models.
-Ethical approvals: are mentioned twice (once at the start of the methods and once at the end) and in fact again on page 41. Response: Any duplication has been cut.
- Figures 1 and 2 are probably unnecessary Response: These have been removed.
Minor points
There are some typos and other errors to sort -e.g. confusion over < and > signs; spelling of "asymmetries"; practice vs practise; other issues to proofread out. Response: these have been carefully checked.
Reviewer: 2 Reviewer Name: Nick Preston Institution and Country: University of Leeds, UK please state any competing interests or state "None declared". This protocol describes the conduct of an important research project that could have a profound impact on rehabilitation of children with unilateral cerebral palsy, and could achieve potentially large benefits for their independence and quality of life. The protocol appears robust and is thorough. I have raised a small number of points to consider.
Q1: I note that you are stratifying children for the randomisation process. This is stated in the flow diagram but not in the Methods section. It is essential that all of the stratifying factors are listed in this protocol.
Response: Yes this is an important point and has been added on page 14 to read:
In figure 1 and on page 14: Central stratification for age at entry (age 3-4 months versus 5-6 months), gender (male vs female), side of lesion (left vs right) then randomise
Have you considered children"s MACS level as a stratifying factor? Response: The MACs is an outcome classification at 24 months and therefore not a stratifying factor at baseline.
Q2: Please also list apriori all covariates for the regression analyses. It is essential to carefully consider all possible confounding and interacting factors and list them prior to the study and prior to the analyses. I suggest that dose received is not a confounding factor (it has an influence on the outcome but not on the exposure, and is therefore a mediator). Response: Thank you for the suggestion. We have edited the statistical analsysis subsection of the manuscript to more carefully define the models we will use. The appropriate section of the text now reads: "The primary outcome, mini-AHA scores at 12 months c.a., will be compared between treatment groups using generalized linear models. The main effect entered will be treatment group (mCMIT/BIM), and stratification variables (age, gender, side) will be entered as covariables. The distributional family will be Gaussian and the identity link will be used."
Q3: Thank you for including your power calculations but they do not take into account the covariates which you will include in the regression analyses, the number of which will have an inverse influence on the RCT"s power. It would be devastating to conduct this study only to find it is drastically underpowered and the results worthless. Response: Please see the response to the above question -the primary analysis of this trial will include only treatment allocation group as a main effect in the primary model, and the only covariables included are the stratification factors (age, sex, side) Q4: Is the GMFCS necessary as well as MACS? I am not sure that it is even appropriate at the age at which you are recruiting your children but will it add anything useful? Both the GMFCS and MACs will be applied at 12 and 24 months C.A. not at study entry ( ≤6 months) as yes both the GMFCS and MACs are not appropriate at ≤ 6 months.
Q4: I also have doubts about the Prechtl's assessment of general movements as a study assessment for inclusion criteria. If used on all infants born in the recruitment period it would give an entirely unsatisfactory indication of children likely to develop neurodevelopmental outcomes (approximately 1 in 26 of the children it suggests will have neurodevelopmental problems will go on to develop them, based on 95% sensitivity and specificity). If you are using it on the 364 children that you think are already at risk, based on the MRI scans, I am not sure it adds anything.
Response: On the contrary the GMs at fidgety age has summary estimated of 98% sensitivity (95%CI 74-100%) and 91% specificity 995%CI 83%-93%), which is superior to MRI (sensitivity ranged from 86-100%) and CUS (74% sensitivity, 92% specificity) as reported in our systematic review of tests to predict cerebral palsy in young children (Bosanquet DMCN 2013) . Based on our review GMs at fidgety age and MRI at term are best.
Reviewer: 3 Reviewer Name: Stephanie DeLuca Institution and Country: Virginia Tech Carilion Research Institute, Roanoke, VA USA Please state any competing interests or state "None declared": None Please leave your comments for the authors below In general, I am not really in favour of publishing 'study plans', but this appears to be a current trend. The paper is well written and presented and the study protocol and plans are excellent.
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